The Miriam Hospital and The Warren Alpert Medical School of Brown University, CBPM, Coro West, 1 Hoppin Street, Providence, RI 02903, USA.
Antiviral Res. 2010 Dec;88 Suppl 1(Suppl 1):S40-6. doi: 10.1016/j.antiviral.2010.09.008.
The clinical evaluation of microbicide formulations presents variable and interacting challenges. Specific domains of acceptability, pharmacokinetics, and toxicity interact with each other to potentially inhibit or enhance a microbicide's efficacy. Each of these is further influenced by application and use parameters in the relative presence (or absence) of vaginal and/or seminal fluids, ultimately impacting effectiveness. Historically, acceptability of formulation and use parameters, and their concomitant behavioral influences, have been considered separately from pharmacokinetics and toxicity. While independent evaluation of these elements is necessary in some respects, we must acknowledge that this approach is not sufficient for the successful development of microbicides. Each needs to be considered in an integrated clinical evaluation strategy. This article presents the rationale for such an approach. This article forms part of a special supplement covering two presentations on clinical evaluation of microbicides from the symposium on "Recent Trends in Microbicide Formulations" held on 25 and 26 January 2010, Arlington, VA.
杀微生物剂制剂的临床评估提出了可变和相互作用的挑战。可接受性、药代动力学和毒性的特定领域相互作用,可能抑制或增强杀微生物剂的疗效。这些领域中的每一个都受到阴道和/或精液液存在(或不存在)情况下应用和使用参数的进一步影响,最终影响有效性。从历史上看,制剂和使用参数的可接受性及其伴随的行为影响,已经分别从药代动力学和毒性方面进行了考虑。虽然在某些方面需要对这些因素进行独立评估,但我们必须认识到,这种方法对于杀微生物剂的成功开发是不够的。需要在综合临床评估策略中考虑每一个因素。本文介绍了这种方法的基本原理。本文是 2010 年 1 月 25 日和 26 日在弗吉尼亚州阿灵顿举行的“杀微生物剂配方的最新趋势”专题讨论会上关于杀微生物剂临床评估的两个报告的特刊的一部分。